Cargando…

The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective

SIMPLE SUMMARY: Breast cancer is the most diagnosed malignancy in woman worldwide and, despite the availability of new innovative therapies, it remains the first cause of death for tumor in woman. 20% of all breast cancer cases are HER2 positive, meaning that they are characterized by an aberrant ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fogazzi, Valentina, Kapahnke, Marcel, Cataldo, Alessandra, Plantamura, Ilaria, Tagliabue, Elda, Di Cosimo, Serena, Cosentino, Giulia, Iorio, Marilena V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657949/ https://www.ncbi.nlm.nih.gov/pubmed/36358746 http://dx.doi.org/10.3390/cancers14215326

Ejemplares similares

Breast Cancer Drug Resistance: Overcoming the Challenge by Capitalizing on MicroRNA and Tumor Microenvironment Interplay
por: Cosentino, Giulia, et al.
Publicado: (2021)

MicroRNA and Oxidative Stress Interplay in the Context of Breast Cancer Pathogenesis
por: Cosentino, Giulia, et al.
Publicado: (2019)

MiR-302b as a Combinatorial Therapeutic Approach to Improve Cisplatin Chemotherapy Efficacy in Human Triple-Negative Breast Cancer
por: Cataldo, Alessandra, et al.
Publicado: (2020)

MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers
por: Plantamura, Ilaria, et al.
Publicado: (2018)

miR-205 in Breast Cancer: State of the Art
por: Plantamura, Ilaria, et al.
Publicado: (2020)

What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
por: Pizzamiglio, Sara, et al.
Publicado: (2021)

miR-9-Mediated Inhibition of EFEMP1 Contributes to the Acquisition of Pro-Tumoral Properties in Normal Fibroblasts
por: Cosentino, Giulia, et al.
Publicado: (2020)

MiR-205 as predictive biomarker and adjuvant therapeutic tool in combination with trastuzumab
por: Cataldo, Alessandra, et al.
Publicado: (2018)

MicroRNAs and metabolic disorders – where are we heading?
por: Sliwinska, Agnieszka, et al.
Publicado: (2017)

Increased Sensitivity to Chemotherapy Induced by CpG-ODN Treatment Is Mediated by microRNA Modulation
por: De Cecco, Loris, et al.
Publicado: (2013)

MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going
por: Cuttano, Roberto, et al.
Publicado: (2022)

End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO
por: Di Cosimo, Serena, et al.
Publicado: (2023)

Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going
por: Boscarino, Giovanni, et al.
Publicado: (2023)

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy
por: Di Cosimo, Serena, et al.
Publicado: (2020)

“Omics” and Immunologic Approaches to Optimizing Cure Rates in HER2-Positive Breast Carcinomas
por: Tagliabue, Elda, et al.
Publicado: (2014)

The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?
por: Castagnoli, Lorenzo, et al.
Publicado: (2019)

MicroRNAs and Triple Negative Breast Cancer
por: D’Ippolito, Elvira, et al.
Publicado: (2013)

The Therapeutic Potential of MicroRNAs in Cancer: Illusion or Opportunity?
por: Fortunato, Orazio, et al.
Publicado: (2020)

miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response
por: Cataldo, Alessandra, et al.
Publicado: (2015)

Predicting the Efficacy of HER2-Targeted Therapies: A Look at the Host
por: Di Modica, Martina, et al.
Publicado: (2017)

Worldwide SARS-CoV-2 haplotype distribution in early pandemic
por: Cairo, Andrea, et al.
Publicado: (2022)

Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
por: Morè, Sonia, et al.
Publicado: (2022)

Dental genetics in Brazil: Where we are
por: Casado, Priscila L., et al.
Publicado: (2018)

Intratumor lactate levels reflect HER2 addiction status in HER2‐positive breast cancer
por: Castagnoli, Lorenzo, et al.
Publicado: (2018)

Perspectives on MicroRNA Study in Oncogenesis: Where Are We?
por: Jiang, Shuai
Publicado: (2020)

Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now?
por: Teixeira, Ana L, et al.
Publicado: (2014)

Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023)

The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine
por: Di Modica, Martina, et al.
Publicado: (2022)

Vesicoureteral Reflux: Where Have We Been, Where Are We Now, and Where Are We Going?
por: McLorie, Gordon A.
Publicado: (2008)

TSACO’s Third Anniversary: where we were, where we are, and where we’re going
por: Fabian, Timothy
Publicado: (2019)

Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?
por: Ricco, Gianluca, et al.
Publicado: (2021)

The Clusmy Child: Where Are We and Where Are We Going?
por: Hadders-Algra, Mijna, et al.
Publicado: (2003)

European HEPnet: where we are and where we are going
por: Carpenter, B E, et al.
Publicado: (1990)

Iron health: where are we and where are we going?
por: Gotardo, Glória Ines Beal
Publicado: (2011)

Animal Sentience: Where are We and Where are We Heading?
por: Proctor, Helen
Publicado: (2012)

Hip Arthroscopy: Where We Are, and Where We Are Going
por: Park, Myung Sik, et al.
Publicado: (2015)

Bioactive Glasses: Where Are We and Where Are We Going?
por: Baino, Francesco, et al.
Publicado: (2018)

Diabetic cardiomyopathy: where we are and where we are going
por: Lee, Wang-Soo, et al.
Publicado: (2017)

Obstetric ultrasound: where are we and where are we going?
por: Abramowicz, Jacques S
Publicado: (2021)

Hidradenitis Suppurativa: Where We Are and Where We Are Going
por: Scala, Emanuele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_72umd48ilu72pkln1alndq9kfc